DAWN — Day One Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.22bn
- $1.77bn
- $158.18m
Annual income statement for Day One Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 131 | 158 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 126 | 141 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 72.7 | 147 | 206 | 240 | 286 |
| Operating Profit | -72.7 | -147 | -206 | -109 | -128 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -72.8 | -142 | -189 | -88.4 | -109 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -72.8 | -142 | -189 | -95.5 | -107 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -171 | -142 | -189 | -95.5 | -107 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -171 | -142 | -189 | -95.5 | -107 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.62 | -2.17 | -2.37 | -1.78 | -1.04 |